218 related articles for article (PubMed ID: 33431414)
1.
Lasko MJ; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33431414
[TBL] [Abstract][Full Text] [Related]
2. In vivo activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β-lactamase-producing Enterobacterales and Pseudomonas aeruginosa in the neutropenic murine thigh infection model.
Gill CM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Mar; 76(4):993-1000. PubMed ID: 33438033
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Lasko MJ; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
Kidd JM; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteria.
Abdelraouf K; Almarzoky Abuhussain S; Nicolau DP
J Antimicrob Chemother; 2020 Dec; 75(12):3601-3610. PubMed ID: 32862218
[TBL] [Abstract][Full Text] [Related]
6.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
7. The paradoxical in vivo activity of β-lactams against metallo-β-lactamase-producing Enterobacterales is not restricted to carbapenems.
Abdelraouf K; Reyes S; Nicolau DP
J Antimicrob Chemother; 2021 Feb; 76(3):684-691. PubMed ID: 33179050
[TBL] [Abstract][Full Text] [Related]
8.
Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
[TBL] [Abstract][Full Text] [Related]
9. In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
Gethers M; Chen I; Abdelraouf K; Nicolau DP
J Antimicrob Chemother; 2022 Jun; 77(7):1931-1937. PubMed ID: 35411395
[TBL] [Abstract][Full Text] [Related]
10. Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model.
Lasko MJ; Nicolau DP; Asempa TE
J Antimicrob Chemother; 2022 Feb; 77(2):443-447. PubMed ID: 34747449
[TBL] [Abstract][Full Text] [Related]
11.
Monogue ML; Tabor-Rennie J; Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31235557
[TBL] [Abstract][Full Text] [Related]
12. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
[TBL] [Abstract][Full Text] [Related]
13. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β-lactamase-producing Enterobacterales in the neutropenic murine thigh infection model.
Gill CM; Asempa TE; Nicolau DP
J Antimicrob Chemother; 2021 Jan; 76(1):184-188. PubMed ID: 33103202
[TBL] [Abstract][Full Text] [Related]
16. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
[TBL] [Abstract][Full Text] [Related]
17. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.
Mushtaq S; Vickers A; Chaudhry A; Woodford N; Livermore DM
J Antimicrob Chemother; 2022 Jun; 77(7):1916-1922. PubMed ID: 35368056
[TBL] [Abstract][Full Text] [Related]
18. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
[TBL] [Abstract][Full Text] [Related]
20.
Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
